company background image
ENTX

Entera Bio NasdaqCM:ENTX Stock Report

Last Price

US$1.19

Market Cap

US$34.3m

7D

-8.5%

1Y

-75.3%

Updated

24 Sep, 2022

Data

Company Financials +
ENTX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth5/6
Past Performance0/6
Financial Health6/6
Dividends0/6

ENTX Stock Overview

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs.

Entera Bio Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Entera Bio
Historical stock prices
Current Share PriceUS$1.19
52 Week HighUS$5.24
52 Week LowUS$1.14
Beta2.07
1 Month Change-15.00%
3 Month Change-26.54%
1 Year Change-75.26%
3 Year Change-52.21%
5 Year Changen/a
Change since IPO-81.05%

Recent News & Updates

Aug 11

Entera Bio GAAP EPS of -$0.24 , revenue of $0.11M

Entera Bio press release (NASDAQ:ENTX): 1H GAAP EPS of -$0.24. Revenue of $0.11M (-59.3% Y/Y). Shares +3.68% PM

Shareholder Returns

ENTXUS BiotechsUS Market
7D-8.5%-5.0%-5.2%
1Y-75.3%-30.0%-23.0%

Return vs Industry: ENTX underperformed the US Biotechs industry which returned -30% over the past year.

Return vs Market: ENTX underperformed the US Market which returned -23.1% over the past year.

Price Volatility

Is ENTX's price volatile compared to industry and market?
ENTX volatility
ENTX Average Weekly Movement11.8%
Biotechs Industry Average Movement11.1%
Market Average Movement6.9%
10% most volatile stocks in US Market15.8%
10% least volatile stocks in US Market2.8%

Stable Share Price: ENTX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: ENTX's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
200922Miranda Toledanohttps://www.enterabio.com

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company’s lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses.

Entera Bio Ltd. Fundamentals Summary

How do Entera Bio's earnings and revenue compare to its market cap?
ENTX fundamental statistics
Market CapUS$34.28m
Earnings (TTM)-US$14.28m
Revenue (TTM)US$417.00k

82.2x

P/S Ratio

-2.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ENTX income statement (TTM)
RevenueUS$417.00k
Cost of RevenueUS$288.00k
Gross ProfitUS$129.00k
Other ExpensesUS$14.41m
Earnings-US$14.28m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.50
Gross Margin30.94%
Net Profit Margin-3,425.18%
Debt/Equity Ratio0%

How did ENTX perform over the long term?

See historical performance and comparison